The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...
South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK ...
ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology t ...
GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases.
A groundbreaking collagen-based dermal filler has officially launched in the Philippines, promising a new approach to facial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results